Bcl-2 in Combination to Myeloid Antigen Expression in Adult Acute Lymphoblastic Leukemia and Prognostic Outcome

Authors: Amirghofran, Zahra; Daneshbod, Yahya; Gholijani, Naser

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 17, Number 10, October 2009 , pp. 447-454(8)

Publisher: Cognizant Communication Corporation

Buy & download fulltext article:

OR

Price: $79.00 plus tax (Refund Policy)

Abstract:

The present study was performed to find the importance of two myeloid (CD13 and CD33) antigens aberrantly expressed on the blasts of acute lymphoblastic leukemia (ALL) patients and Bcl-2 expression in relation to clinical and biological features and treatment outcome. Bone marrow or peripheral blood samples of 50 patients were assessed for the expression of markers by immunostaining methods. Twenty-one patients (42%) showed more than 20% positivity for Bcl-2. Aberrant expression of myeloid antigens was found in 14% of cases. The expression of Bcl-2 was associated with shorter survival (p = 0.009). A significant correlation between expression of myeloid antigens (MY) and survival and complete remission duration was found. The mean survival was 656 ± 301 days for MY+ cases and 1,009 ± 230 days for MY patients (p < 0.0001). Expression of Bcl-2 in combination to myeloid antigens was associated with a poorer outcome. Survival of MY+ patients expressing Bcl-2 was shorter than MY Bcl-2+ and MY+ Bcl-2 ALL cases (p = 0.038). In conclusion, results of this study indicated the prognostic value of Bcl-2 and myeloid antigen expression in ALL patients. Presence of these markers together on the leukemic cells was associated with a poorer response to therapy and may implicate modified therapeutic strategies in the patients.

Keywords: Acute lymphoblastic leukemia; Bcl-2; Myeloid antigens

Document Type: Research Article

DOI: http://dx.doi.org/10.3727/096504009789735413

Publication date: October 1, 2009

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page